TrumpRx Discounts Cut Drug Prices

A federal cash‑discount program (TrumpRx), combined with Medicare negotiation and voluntary price agreements with major manufacturers, is associated with a sharp 2026 decline in the Consumer Price Index for prescription drugs (reported −4.5% year‑over‑year). The program appears especially to have reduced prices and expanded access for high‑use, high‑cost GLP‑1 obesity drugs, lowering out‑of‑pocket costs for uninsured and noncovered patients. — If true and sustained, policy‑driven retail discounts plus negotiated deals can rapidly lower drug prices, reshaping debates over market vs. regulatory levers for drug affordability and access.